<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63950">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02153437</url>
  </required_header>
  <id_info>
    <org_study_id>CV205-006</org_study_id>
    <nct_id>NCT02153437</nct_id>
  </id_info>
  <brief_title>Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers</brief_title>
  <official_title>A Study of the Effects of BMS-919373 on Atrial Effective Refractory Period in Subjects With a Dual-Chamber Pacemaker</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effect of  our compound (BMS-919373) on electrical activity of the heart
      using pacemakers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>The effect of BMS-919373 on Atrial effective refractory period (AERP) in subjects with a dual chamber pacemaker</measure>
    <time_frame>At 0.5, 1, 2, and 4 hours following study drug administration</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety assessments will be based on Adverse event reports, vital sign measurements, Electrocardiogram (ECGs), physical examinations and clinical laboratory tests</measure>
    <time_frame>At 1, 2, and 4 hours following study drug administration</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments based on Ventricular Effective Refractory Period (VERP) and change from baseline</measure>
    <time_frame>At 2 hour following study drug administration</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments based on Atrioventricular interval (AVI) and change from baseline</measure>
    <time_frame>At 1, 2, and 4 hours following study drug administration</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments based on Wenckebach cycle length (WCL) and change from baseline</measure>
    <time_frame>At 1, 2, and 4 hours following study drug administration</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments based on Intra-atrial conduction time (IACT) and change from baseline</measure>
    <time_frame>At 1, 2, and 4 hours following study drug administration</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Arm A: BMS-919373</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-919373 oral Solution single dose for one day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Sotalol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sotalol oral Tablet single dose for one day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Placebo for BMS-919373</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral solution one single dose for one day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-919373</intervention_name>
    <arm_group_label>Arm A: BMS-919373</arm_group_label>
    <other_name>iKUR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sotalol</intervention_name>
    <arm_group_label>Arm B: Sotalol</arm_group_label>
    <other_name>Co Sotalol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for BMS-919373</intervention_name>
    <arm_group_label>Arm C: Placebo for BMS-919373</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Eligible patients will have a  dual-chamber permanent pacemaker without a history of
             atrial fibrillation

          -  Women who are not of childbearing potential

        Exclusion Criteria:

          -  History of Transient Ischemic Attack (TIA) or stroke in the last 12 months

          -  History of clinically significant ventricular arrhythmia (not including isolated
             monomorphic Premature Ventricular Contractions (PVCs)). Such arrhythmias are marked
             by loss of consciousness, emergent cardioversion or defibrillation or unstable vital
             signs requiring medical intervention

          -  Complete heart block

          -  Planned surgery, endovascular intervention or cardioversion within the study period

          -  Use of Statin therapy

          -  History of atrial fibrillation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>May 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sotalol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
